• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用小分子疗法管理中重度溃疡性结肠炎患者的实用指南。

Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies.

作者信息

Jairath Vipul, Afif Waqqas, Bressler Brian, Pope Janet E, Selchen Daniel, Targownik Laura E, Panaccione Remo

机构信息

Division of Gastroenterology, Western University, St. Joseph's Health Care, London, ON, Canada.

Division of Gastroenterology and Hepatology, McGill University, Montreal General Hospital, Montreal, QC H3G 1A4, Canada.

出版信息

J Can Assoc Gastroenterol. 2024 May 15;7(4):282-289. doi: 10.1093/jcag/gwae013. eCollection 2024 Aug.

DOI:10.1093/jcag/gwae013
PMID:39139217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11317630/
Abstract

Ulcerative colitis (UC) is a severe and debilitating illness that affects the quality of life and physical health of many Canadians. Given the dynamic and progressive nature of the disease, advanced therapies are required to support its long-term management. The emergence of small molecule therapies offers novel treatment options that target mechanisms central to the immunopathology of UC. Sphingosine-1-phosphate (S1P) receptor modulators and Janus-activated kinase inhibitors are 2 classes of therapies that target unique pathways to attenuate inflammation and modulate the immune response characteristic of UC. This review aims to provide practical guidance on how these therapeutic options can best be used to optimize treatment management and highlight the emerging role of small molecule therapies as a treatment strategy for UC.

摘要

溃疡性结肠炎（UC）是一种严重且使人衰弱的疾病，影响着许多加拿大人的生活质量和身体健康。鉴于该疾病具有动态性和渐进性，需要先进的疗法来支持其长期管理。小分子疗法的出现提供了新的治疗选择，这些疗法针对溃疡性结肠炎免疫病理学的核心机制。鞘氨醇-1-磷酸（S1P）受体调节剂和Janus激活激酶抑制剂是两类针对独特途径以减轻炎症和调节溃疡性结肠炎特征性免疫反应的疗法。本综述旨在就如何最佳利用这些治疗选择来优化治疗管理提供实用指导，并强调小分子疗法作为溃疡性结肠炎治疗策略的新兴作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a87e/11317630/8a7334e814d1/gwae013_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a87e/11317630/0efa8b62d0b4/gwae013_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a87e/11317630/2f08c05b3525/gwae013_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a87e/11317630/8a7334e814d1/gwae013_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a87e/11317630/0efa8b62d0b4/gwae013_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a87e/11317630/2f08c05b3525/gwae013_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a87e/11317630/8a7334e814d1/gwae013_fig3.jpg

相似文献

1
Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies.使用小分子疗法管理中重度溃疡性结肠炎患者的实用指南。
J Can Assoc Gastroenterol. 2024 May 15;7(4):282-289. doi: 10.1093/jcag/gwae013. eCollection 2024 Aug.
2
An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.奥扎莫德作为一种治疗成人中重度活动性溃疡性结肠炎的治疗选择的概述。
Expert Opin Pharmacother. 2022 Jun;23(8):893-904. doi: 10.1080/14656566.2022.2071605. Epub 2022 May 9.
3
Ulcerative Colitis in Adults: A Review.成人溃疡性结肠炎：综述。
JAMA. 2023 Sep 12;330(10):951-965. doi: 10.1001/jama.2023.15389.
4
Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease.鞘氨醇-1-磷酸受体调节剂：炎症性肠病口服治疗的新一波浪潮。
Gastroenterol Hepatol (N Y). 2022 May;18(5):265-271.
5
The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.溃疡性结肠炎患者接受高级治疗后缓解的发生率和治疗反应不足的指标：来自英国病历的结果。
Curr Med Res Opin. 2023 May;39(5):681-689. doi: 10.1080/03007995.2023.2194782. Epub 2023 Apr 18.
6
Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.S1P1受体调节剂药物治疗中重度溃疡性结肠炎患者的疗效与安全性
J Clin Med. 2023 Jul 30;12(15):5014. doi: 10.3390/jcm12155014.
7
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.埃特拉莫德用于溃疡性结肠炎的诱导和维持治疗（ELEVATE）：两项随机、双盲、安慰剂对照的3期研究。
Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2.
8
Modulation of sphingosine-1-phosphate in ulcerative colitis.溃疡性结肠炎中鞘氨醇-1-磷酸的调节。
Expert Opin Biol Ther. 2020 Apr;20(4):413-420. doi: 10.1080/14712598.2020.1732919. Epub 2020 Feb 25.
9
Oral small molecule agents in management of ulcerative colitis: fact or fancy?溃疡性结肠炎治疗中的口服小分子药物：现实还是幻想？
Turk J Med Sci. 2023 Aug 11;53(6):1526-1536. doi: 10.55730/1300-0144.5722. eCollection 2023.
10
Emerging therapies for the treatment of ulcerative colitis.治疗溃疡性结肠炎的新兴疗法。
Expert Opin Emerg Drugs. 2020 Mar 9:1-9. doi: 10.1080/14728214.2020.1737009.

引用本文的文献

1
Gallic acid serves as an effective therapeutic agent of inflammatory bowel disease: Pharmacological impacts on tight junction-dependent intestinal permeability and its related intracellular signaling.没食子酸是炎症性肠病的有效治疗剂：对紧密连接依赖性肠道通透性及其相关细胞内信号传导的药理学影响
Curr Res Pharmacol Drug Discov. 2025 May 17;8:100223. doi: 10.1016/j.crphar.2025.100223. eCollection 2025.
2
The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis.目前用于治疗溃疡性结肠炎的1-磷酸鞘氨醇受体调节剂
J Clin Med. 2025 May 15;14(10):3475. doi: 10.3390/jcm14103475.

本文引用的文献

1
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.埃特拉莫德用于溃疡性结肠炎的诱导和维持治疗（ELEVATE）：两项随机、双盲、安慰剂对照的3期研究。
Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2.
2
Tofacitinib in the treatment of ulcerative colitis : A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH).托法替尼治疗溃疡性结肠炎：奥地利胃肠病学和肝病学学会（ÖGGH）炎症性肠病工作组发布的立场文件。
Wien Klin Wochenschr. 2023 Jan;135(1-2):1-13. doi: 10.1007/s00508-022-02110-2. Epub 2022 Dec 1.
3
Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease.
鞘氨醇-1-磷酸受体调节剂：炎症性肠病口服治疗的新一波浪潮。
Gastroenterol Hepatol (N Y). 2022 May;18(5):265-271.
4
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.静脉血栓栓塞症与 JAK 抑制剂和其他免疫调节药物：一项在类风湿关节炎患者中进行的瑞典比较安全性研究。
Ann Rheum Dis. 2023 Feb;82(2):189-197. doi: 10.1136/ard-2022-223050. Epub 2022 Sep 23.
5
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective.托法替尼治疗溃疡性结肠炎的定位：全球视角。
Expert Rev Gastroenterol Hepatol. 2022 Aug;16(8):737-752. doi: 10.1080/17474124.2022.2106216. Epub 2022 Aug 2.
6
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.评估乌帕替尼治疗中重度活动期溃疡性结肠炎的疗效：设计、研发及潜在的治疗定位。
Drug Des Devel Ther. 2022 Jun 17;16:1897-1913. doi: 10.2147/DDDT.S340459. eCollection 2022.
7
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
8
Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Induction Period of True North.奥扎莫德诱导中重度活动性溃疡性结肠炎患者出现症状缓解和病情缓解的速度：来自True North诱导期的结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):2-3.
9
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.奥扎莫德用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
10
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.加拿大胃肠病学协会炎症性肠病（IBD）患者免疫接种临床实践指南 - 第2部分：灭活疫苗
J Can Assoc Gastroenterol. 2021 Jul 29;4(4):e72-e91. doi: 10.1093/jcag/gwab016. eCollection 2021 Aug.